文献速递睡眠呼吸障碍

proximal舌下神经刺激治疗OSA的三年结局

Three-Year Outcomes of Proximal Hypoglossal Nerve Stimulation in OSA.
PubMed 文献 · Chest · 2026-02-12

BACKGROUND: Targeted proximal hypoglossal nerve stimulation was shown to improve sleep-disordered breathing, sleep architecture, and quality of life (QOL) with a favorable safety profile over 1 year in the Targeted Hypoglossal Stimulation 3 (THN3) randomized controlled trial.…

要点

  • pHGNS在OSA患者中3年内持续改善AHI、氧合和生活质量。
  • 中位AHI降低在24个月为-15.1/h,36个月为-17.7/h,效应量大。
  • 疗效与dHGNS的3年结果相当,不良事件相对较少。

核心结论

  • pHGNS治疗1年的疗效维持至3年,且不良事件相对较少,与dHGNS反应相似,提示其是安全有效的长期OSA治疗。

研究设计与样本

  • THN3随机对照试验(NCT02263859)纳入AHI 20-65/h且BMI≤35 kg/m2的 enrollees,分析完成预设3年访视的参与者。

主要发现

  • pHGNS在24和36个月时较基线持续改善睡眠呼吸障碍、氧合和生活质量。
  • 中位AHI降低在24个月为-15.1/h(95%CI -18.6,-12.6),36个月为-17.7/h(95%CI -21.9,-15.3),效应量大。
  • 36个月时睡眠呼吸障碍和生活质量获益持续,与dHGNS的3年报告结果相当。

关键数值与推荐

  • THN3入组标准:AHI 20-65/h,BMI≤35 kg/m2。

临床怎么用

  • 对于符合条件的OSA患者,pHGNS可作为长期治疗选择,3年疗效持续且安全性较好。

局限性

  • 仅75%的THN3参与者完成3年随访,可能存在失访偏倚。
  • 与dHGNS的比较为跨试验参照STAR试验,非头对头比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Targeted proximal hypoglossal nerve stimulation was shown to improve sleep-disordered breathing, sleep architecture, and quality of life (QOL) with a favorable safety profile over 1 year in the Targeted Hypoglossal Stimulation 3 (THN3) randomized controlled trial. Herein, THN3 proximal hypoglossal nerve stimulation (pHGNS) 3-year safety and efficacy are profiled with reference to distal hypoglossal nerve stimulation (dHGNS) from the Stimulation Therapy for Apnea Reduction (STAR) trial. RESEARCH QUESTION: What are the long-term safety and efficacy of pHGNS, and how do they compare with dHGNS? STUDY DESIGN AND METHODS: THN3 (NCT02263859) enrollees had an apnea-hypopnea index (AHI) 20-65/hr and BMI ≤ 35 kg/m2. Participants completing the prespecified 3-year visit were analyzed. Outcomes included adverse events, AHI, Oxygen Desaturation Index, percentage of sleep time with oxygen saturation <90%, and QOL. pHGNS responses at 24 and 36 months were compared with baseline and 11 months of therapy (months 12/15). pHGNS and dHGNS results were compared through 36 months. RESULTS: One hundred four of 138 (75%) THN3 participants completed 3-year follow-up. pHGNS delivered sustained improvements in sleep-disordered breathing, oxygenation, and QOL at months 24 and 36 vs baseline. Long-term outcomes were comparable to those at 11 months of treatment: median AHI reductions were -15.1/h (95% CI, -18.6, -12.6) and -17.7/h (-21.9, -15.3) with large effect sizes; probabilities of superiority vs baseline were 0.79 (0.72-.87) and 0.79 (0.70-.87), respectively. Benefits in sleep-disordered breathing and QOL were sustained at 36 months and appeared to be comparable to those reported for dHGNS at 3 years. INTERPRETATION: Therapeutic responses to pHGNS at 1 year were maintained through 3 years with relatively few adverse events. Similarities in responses to dHGNS suggest that pHGNS provides safe and efficacious long-term OSA treatment. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT02263859; URL: www. CLINICALTRIALS: gov.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Schwartz AR, Jacobowitz O, Mickelson SA, et al. Three-Year Outcomes of Proximal Hypoglossal Nerve Stimulation in OSA. Chest. 2026. PMID: 41690459. doi:10.1016/j.chest.2025.11.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。